In-vitro characterisation of a novel antimicrobial agent, TNP-2092, against Helicobacter pylori clinical isolates

In-vitro characterisation of a novel antimicrobial agent, TNP-2092, against Helicobacter pylori clinical isolates

BACKGROUND AND OBJECTIVES TNP-2092 is a novel dual-action lead compound consisting of rifamycin SV and 4H-4-oxo-quinolizine pharmacophores, with a broad spectrum of antibacterial activities. This compound is currently in the early stage of clinical development for Helicobacter pylori inf...

Full description

Bibliographic Details
Main Authors: Ben Wang, Qiaoyun Zhao, Wenzhu Yin, Ying Yuan, Xiaomei Wang, You-hua Wang, Hui Wang, Wen Ye, Shuping Chen, Hai-long Guo, Yong Xie
Format: Article
Language:English
Published: SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2018-07-01
Series:Swiss Medical Weekly
Subjects:
Helicobacter pylori
drug resistant
Online Access:https://www.smw.ch/index.php/smw/article/view/2501

Internet

https://www.smw.ch/index.php/smw/article/view/2501

Similar Items